

Friday October 18th, 2019

CMWP SC meetings (part I)

Open to EBMT members only

8:00	9:00 Welcome	
9:00	9:10 Introduction	I.Yakoub-Agha P. Hayden
9:10	10:10 Plasma cell disorders subcommittee projects presentation	S. Schönland M. Peksac
10:10	11:20 Myelodysplastic syndromes including CMML subcommittee projects presentation	M. Robin (TBC) F. Onida (TBC) C. Scheid (TBC)
11:20	12:30 PH-negative myeloproliferative syndromes subcommittee projects presentation	D. McLornan T. Czerw (TBC) JC Hernández Bolud (TBC)
12:30	13:00 Practice harmonisation and guidelines subcommittee	P. Hayden L. Garderet (TBC)

13:00 14:30 Sponsored Lunch Symposium (open to all)

CMWP SC meetings (Part II)

Open to EBMT members only

14:30	15:30 Chronic myeloid leukemia subcommittee projects presentation	Y. Chalandon (TBC)
15:30	16:30 Chronic lymphoid leukemia subcommittee projects presentation	O. Tourniac (TBC) M. Van Gelder (TBC)
16:30	Closing remarks	

Saturday October 19th, 2019

Educational Session

Open to all

9:00	10:00 Welcome	
10:00	10:10 Introduction	I.Yakoub-Agha
	Myelofibrosis	
	Chair Y.Chalandon (TBC)	
10:10	10:30 Is there a role for Ruxolitinib treatment prior to transplantation: Yes	N. Kroeger
10:30	10:50 Is there a role for Ruxolitinib treatment prior to transplantation: No	D. McLornan
	Chronic Lymphocytic Leukemia	
	Chair M. Van den Gelder (TBC)	
10:50	11:10 Management of T-PLL	O. Tourniac (TBC)
11:10	11:30 Role of Venetoclax for transplant eligible patients	O. Arslan
11:30	12:00 Coffee Break	
	Myelodysplastic Syndrome	
	Chair M. Robin (TBC)	
12:00	12:20 TP53 inhibitors	P. Fenaux (TBC)
12:20	12:40 Azacytidine treatment following transplant	Z. Gulbaş

12:40 14:10 Sponsored Lunch Symposium (open to all)

Multiple myeloma

Chair S.Schoenland (TBC)

14:20	14:40 Frontline ASCT	L.Rosinol
14:40	15:00 Delayed ASCT	M.Beksac
15:00	15:20 Treatment of Transplant ineligible patients	T.Facon (TBC)
15:20	15:40 Coffee Break	

Cellular Therapies

Chair S. Ratip

15:40	16:00 Bi- and tri-specific monoclonal antibodies	H. Einsele (TBC)
16:00	16:20 CARs	F. Ciceri (TBC)
16:20	16:40 EBMT recommendations for CAR treatment	P. Hayden (TBC)

Graft versus Host Disease

Chair O. Ilhan

16:40	17:00 Ibrutinib for treatment of GVHD: Turkish experience	S. Civriz (TBC)
17:00	Conclusion	M. Beksac